Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?

Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.

Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.